<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Between May 1995 and April 1996, 20 patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease were successfully treated with interferon alpha(2a) (IFN-alpha(2a)) 9 million IU/day three times a week and 16 patients with <z:chebi fb="0" ids="23359">colchicine</z:chebi> 1.5 mg/day orally for 3 months </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To study the long-term effects of IFN treatment in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Between the years of 1996 and 1999, the patients were followed up every 3 months or whenever indicated </plain></SENT>
<SENT sid="3" pm="."><plain>Retrospective evaluation was performed </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In 56% of the patients with complete remission or partial remission at the end of IFN-alpha(2a) treatment, long-term remissions ranging from 36 to 48 months were observed </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: IFN-alpha(2a) treatment is an effective treatment modality in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease with the advantage of inducing prolonged remissions </plain></SENT>
</text></document>